Pay in 4 interest-free payments of $7.02 Learn more
Ships within 48 hours · Estimated delivery Oct 18 - Oct 23
BLU-945, a selective EGFR inhibitor, was tested in EGFR-mutated NSCLC (NCT04862780), while daraxonrasib, a RAS(ON) multiselective noncovalent tri-complex inhibitor, is being evaluated in both NSCLC (NCT06881784) and PDAC (NCT06625320)
Reported adverse effects are those typical of topical products: local irritation, redness, and contact sensitivity in some users
The star ingredients of this product that the company highlights include: Copper tripeptide complex (GHK-Cu) Copper lysinate complex Acetyl hexapeptide-8 complex Saccharide isomerate Ectoine Insider Tip: It can be a bit confusing, but ectoin and ectoine are the same thing
Daily home dosing eliminates clinic visits required for IV administration
(2012) 129:e2516
